Navigating the high costs of GLP-1 medications while providing employees with the best possible coverage is a growing challenge for employers. These groundbreaking drugs are transforming the weight loss landscape, and as their popularity soars, so does the need for a balanced solution. And now WeightWatchers for Business has a new employer model for expanding GLP-1 coverage.
The News:
Introducing WeightWatchers RxFlexFund™, a first-of-its-kind solution designed to help employers provide access to these in-demand medications through responsible prescribing and cost-effective funding. This program combines direct pricing from pharmaceutical manufacturers with flexible employer subsidy coverage for GLP-1s, integrated with WeightWatchers’ full-spectrum behavioral and clinical support.
With WeightWatchers RxFlexFund, employers cover the cost of WeightWatchers Clinic and contribute a set percentage of medication costs, ranging from 25% to 75%, to help offset the impact of GLP-1 medication costs for their employees. Through this solution, employers also gain access to direct manufacturer pricing, providing transparent, competitive costs. The result is a solution that not only helps organizations control costs and budget with predictability, but also offers their employees a comprehensive path to lasting results.
Who Benefits:
Organizations through access to best direct manufacturer pricing, cost and budget predictability, flexibility of subsidy coverage, comprehensive outcomes reporting, and improved employee satisfaction and retention
Members with lower medication pricing, access to quality, FDA-approved medications, concierge care with WeightWatchers Clinic, WeightWatchers’ wraparound behavior change program with nutritional support designed for those taking GLP-1s, and access to registered dietitians and fitness specialists for improved outcomes and lasting results
By offering a strategic and supportive solution for GLP-1 access, organizations can improve employee satisfaction and retention while protecting their bottom line.
To learn more, read the press release or contact us.